 WALTHAM, Mass., March 25, 2021 GLOBE NEWSWIRE -- EyeGate Pharmaceuticals, Inc. NASDAQ: EYEG, EyeGate or the Company, a clinical-stage company developing and commercializing products for treating inflammatory and immune diseases with a focus on the eye and nervous system, today announced financial results for the year ended December 31, 2020 and provided an update on recent corporate and operational activities. 